gujarat terce laboratories has approved the re-appointment of Mr. Aalap Prajapati as Managing Director & Chief Executive Officer for a period of five years. The decision was taken by the Board of Directors at its meeting held on 29 May 2026, based on the recommendations of the Nomination and Remuneration Committee. The re-appointment is subject to the approval of shareholders at the ensuing 41st Annual General Meeting of the Company.

Mr. Aalap Prajapati (DIN: 08088327) is liable to retire by rotation and will serve as Managing Director & CEO with effect from 28 October 2026 to 27 October 2031. He brings over 15 years of experience in the pharmaceutical and healthcare industry, with expertise in business strategy, operations management, marketing, and business development. He holds a management qualification from B.K. School of Business Management with specialization in Marketing and Operations.

The disclosure regarding the re-appointment was made pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the details comply with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023.

Mr. Prajapati is the son of Mr. Natwarbhai Prajapati, the Whole-Time Director of the Company. The Board confirmed that Mr. Aalap Prajapati is not debarred from holding the office of director by virtue of any SEBI order or any other such authority, as per disclosures required under BSE and NSE circulars dated 20 June 2018.

Key Details of Re-appointment

Gujarat Terce Laboratories has intimated BSE Limited of an upcoming Board of Directors meeting, scheduled for Wednesday, May 27, 2026. The intimation, dated May 13, 2026, was filed in compliance with Regulation 29 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board of Directors is set to convene to deliberate on key corporate matters. The following items are on the agenda for the meeting:

• Consider and approve the Annual Audited Standalone Financial Results of the company for the fourth quarter and financial year ended March 31, 2026
• Consider matters related to the ensuing Annual General Meeting of the company

The key details of the scheduled board meeting are summarised below:

Trading Window Closure

In accordance with the company's Code of Conduct for Prevention of Insider Trading in Securities of Gujarat Terce Laboratories, the Trading Window has been closed from Wednesday, April 1, 2026 to Friday, May 29, 2026, both days inclusive, in connection with the consideration of the said financial results.

The intimation has also been uploaded on the company's website and is accessible at https://www.gujaratterce.in/financial-results/ . The filing was signed by Ashka Solanki, Company Secretary, on behalf of Gujarat Terce Laboratories.